142 related articles for article (PubMed ID: 27561186)
1. Risk of hospitalisation after primary treatment for prostate cancer.
Williams SB; Duan Z; Chamie K; Hoffman KE; Smith BD; Hu JC; Shah JB; Davis JW; Giordano SH
BJU Int; 2017 Jul; 120(1):48-55. PubMed ID: 27561186
[TBL] [Abstract][Full Text] [Related]
2. External Beam Radiation Therapy With a Brachytherapy Boost Versus Radical Prostatectomy in Gleason Pattern 5 Prostate Cancer: A Population-Based Cohort Study.
Wang C; Kishan AU; Kamrava M; Steinberg ML; King CR
Int J Radiat Oncol Biol Phys; 2017 Aug; 98(5):1045-1052. PubMed ID: 28721887
[TBL] [Abstract][Full Text] [Related]
3. Cost implications of the rapid adoption of newer technologies for treating prostate cancer.
Nguyen PL; Gu X; Lipsitz SR; Choueiri TK; Choi WW; Lei Y; Hoffman KE; Hu JC
J Clin Oncol; 2011 Apr; 29(12):1517-24. PubMed ID: 21402604
[TBL] [Abstract][Full Text] [Related]
4. Radical prostatectomy vs radiation therapy and androgen-suppression therapy in high-risk prostate cancer.
Westover K; Chen MH; Moul J; Robertson C; Polascik T; Dosoretz D; Katin M; Salenius S; D'Amico AV
BJU Int; 2012 Oct; 110(8):1116-21. PubMed ID: 22540922
[TBL] [Abstract][Full Text] [Related]
5. Radical Prostatectomy or External Beam Radiation Therapy vs No Local Therapy for Survival Benefit in Metastatic Prostate Cancer: A SEER-Medicare Analysis.
Satkunasivam R; Kim AE; Desai M; Nguyen MM; Quinn DI; Ballas L; Lewinger JP; Stern MC; Hamilton AS; Aron M; Gill IS
J Urol; 2015 Aug; 194(2):378-85. PubMed ID: 25711194
[TBL] [Abstract][Full Text] [Related]
6. Morbidity and costs of salvage vs. primary radical prostatectomy in older men.
Prasad SM; Gu X; Kowalczyk KJ; Lipsitz SR; Nguyen PL; Hu JC
Urol Oncol; 2013 Nov; 31(8):1477-82. PubMed ID: 22575240
[TBL] [Abstract][Full Text] [Related]
7. Impact of initial local therapy on survival in men later receiving chemotherapy for prostate cancer: a population-based, propensity-weighted multivariable analysis.
Zabell JR; Adejoro O; Jarosek SL; Elliott SP; Konety BR
World J Urol; 2016 Oct; 34(10):1397-403. PubMed ID: 26914817
[TBL] [Abstract][Full Text] [Related]
8. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
[TBL] [Abstract][Full Text] [Related]
9. Erectile function following brachytherapy, external beam radiotherapy, or radical prostatectomy in prostate cancer patients.
Putora PM; Engeler D; Haile SR; Graf N; Buchauer K; Schmid HP; Plasswilm L
Strahlenther Onkol; 2016 Mar; 192(3):182-9. PubMed ID: 26713323
[TBL] [Abstract][Full Text] [Related]
10. Active treatment in low-risk prostate cancer: a population-based study.
Roy S; Hyndman ME; Danielson B; Fairey A; Lee-Ying R; Cheung WY; Afzal AR; Xu Y; Abedin T; Quon HC
Curr Oncol; 2019 Aug; 26(4):e535-e540. PubMed ID: 31548822
[TBL] [Abstract][Full Text] [Related]
11. Patterns of care for men diagnosed with prostate cancer in Victoria from 2008 to 2011.
Evans SM; Millar JL; Davis ID; Murphy DG; Bolton DM; Giles GG; Frydenberg M; Andrianopoulos N; Wood JM; Frauman AG; Costello AJ; McNeil JJ
Med J Aust; 2013 Jun; 198(10):540-5. PubMed ID: 23725268
[TBL] [Abstract][Full Text] [Related]
12. Survival benefit of definitive therapy in patients with clinically advanced prostate cancer: estimations of the number needed to treat based on competing-risks analysis.
Gandaglia G; Sun M; Trinh QD; Becker A; Schiffmann J; Hu JC; Briganti A; Montorsi F; Perrotte P; Karakiewicz PI; Abdollah F
BJU Int; 2014 Dec; 114(6b):E62-E69. PubMed ID: 24467651
[TBL] [Abstract][Full Text] [Related]
13. Utilizing time-driven activity-based costing to understand the short- and long-term costs of treating localized, low-risk prostate cancer.
Laviana AA; Ilg AM; Veruttipong D; Tan HJ; Burke MA; Niedzwiecki DR; Kupelian PA; King CR; Steinberg ML; Kundavaram CR; Kamrava M; Kaplan AL; Moriarity AK; Hsu W; Margolis DJ; Hu JC; Saigal CS
Cancer; 2016 Feb; 122(3):447-55. PubMed ID: 26524087
[TBL] [Abstract][Full Text] [Related]
14. Satisfaction with Care Among Men with Localised Prostate Cancer: A Nationwide Population-based Study.
Bergengren O; Garmo H; Bratt O; Holmberg L; Johansson E; Bill-Axelson A
Eur Urol Oncol; 2018 May; 1(1):37-45. PubMed ID: 31100227
[TBL] [Abstract][Full Text] [Related]
15. Secondary cancers after intensity-modulated radiotherapy, brachytherapy and radical prostatectomy for the treatment of prostate cancer: incidence and cause-specific survival outcomes according to the initial treatment intervention.
Zelefsky MJ; Pei X; Teslova T; Kuk D; Magsanoc JM; Kollmeier M; Cox B; Zhang Z
BJU Int; 2012 Dec; 110(11):1696-701. PubMed ID: 22889401
[TBL] [Abstract][Full Text] [Related]
16. Sexual function with localized prostate cancer: active surveillance vs radical therapy.
van den Bergh RC; Korfage IJ; Roobol MJ; Bangma CH; de Koning HJ; Steyerberg EW; Essink-Bot ML
BJU Int; 2012 Oct; 110(7):1032-9. PubMed ID: 22260273
[TBL] [Abstract][Full Text] [Related]
17. Surgical management after active surveillance for low-risk prostate cancer: pathological outcomes compared with men undergoing immediate treatment.
Dall'Era MA; Cowan JE; Simko J; Shinohara K; Davies B; Konety BR; Meng MV; Perez N; Greene K; Carroll PR
BJU Int; 2011 Apr; 107(8):1232-7. PubMed ID: 20804478
[TBL] [Abstract][Full Text] [Related]
18. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study.
Culp SH; Schellhammer PF; Williams MB
Eur Urol; 2014 Jun; 65(6):1058-66. PubMed ID: 24290503
[TBL] [Abstract][Full Text] [Related]
19. Radical prostatectomy vs radiotherapy vs observation among older patients with clinically localized prostate cancer: a comparative effectiveness evaluation.
Sun M; Sammon JD; Becker A; Roghmann F; Tian Z; Kim SP; Larouche A; Abdollah F; Hu JC; Karakiewicz PI; Trinh QD
BJU Int; 2014 Feb; 113(2):200-8. PubMed ID: 23937636
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]